You are here

  • Home
  • Archive
  • Volume 10, Issue Suppl 2
  • 850 Interim results for phase 1b dose expansion of MTL-CEBPA in combination with pembrolizumab in patients with advanced solid tumour malignancies

Article metrics

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Combination Immunotherapies
850 Interim results for phase 1b dose expansion of MTL-CEBPA in combination with pembrolizumab in patients with advanced solid tumour malignancies
Free

 

Online download statistics by month:

Online download statistics by month: December 2022 to August 2024

AbstractFullPdf
Dec 202274011
Jan 20233402
Feb 20233802
Mar 20232601
Apr 20234000
May 20235804
Jun 20238804
Jul 20238607
Aug 20233804
Sep 20232402
Oct 20234003
Nov 20236003
Dec 20233803
Jan 20244402
Feb 20243204
Mar 202446030
Apr 20243009
May 20245002
Jun 20242202
Jul 20246405
Aug 20242801
Total9600101